[Efficacy and safety of adalimumab in Crohn's disease]
Tunisie Medicale [La]. 2012; 90 (2): 101-107
em Francês
| IMEMR
| ID: emr-178399
ABSTRACT
Adalimumab is the first subcutaneously self-administered fully human anti-TNFalpha. To determine efficacy and safety of Adalimumab therapy in Crohn disease. Literature review. Adalimumab has been evaluated for its effect in inducing and maintaining remission and its steroid-sparing effect of refractory Crohn's disease. In addition, it offers a significant treatment option in patients who have lost response to or become intolerant to Infliximab. Results also suggest efficacy of Adalimumab in fistulising Crohn's disease but more studies are needed. Adalimumab was well tolerated and studies show that all anti-TNF inhibitors have similar safety profiles
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Fator de Necrose Tumoral alfa
/
Anticorpos Monoclonais Humanizados
Limite:
Humanos
Idioma:
Francês
Revista:
Tunisie Med.
Ano de publicação:
2012
Similares
MEDLINE
...
LILACS
LIS